Augmedix price target raised to $8 from $6 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on Augmedix (AUGX) to $8 from $6 and keeps a Buy rating on the shares after introducing a forecast for 2024. Augmedix is “in a position to become one of the leaders in the burgeoning world of healthcare informatics” as a result of their unique tools and capabilities, an ongoing partnership with Google (GOOGL) and a new opportunity with HCA Healthcare (HCA), argues the analyst, who senses “this company is just scratching the surface of an immense opportunity.”